| abstract |
The present invention relates to shRNA that inhibits vascular endothelial growth factor (VEGF) expression and an anti-tumor pharmaceutical composition comprising the same. In detail, the present invention produced shRNA that inhibits VEGF expression and increased the infection rate by using a lentivirus as a gene delivery agent to significantly improve specificity, delivery capability and expression inhibition ability compared to the prior art, and VEGF expression according to the present invention shRNA inhibits tumor survival, metastasis, and immunosuppression, thereby showing excellent antitumor effects. |